Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The adiponectin receptor (AdipoR) is a 7-pass transmembrane protein. AdipoR2 is mainly found in the liver and has moderate affinity for both full-length and globular adiponectin. AdipoR1 and AdipoR2 are transmembrane proteins with ceramidase activity.
Expression and Distribution of AdipoR2
AdipoR2 is mainly expressed in the liver and expressed in tumor tissues such as breast cancer, colon cancer, and prostate cancer. Studies have shown that AdipoR1 and AdipoR2 are present in macrophages of human atherosclerotic lesions, and AdipoR1 is more abundant in monocytes than in AdipoR2. When differentiated into macrophages, the AdipoR1 expression is decreased and AdipoR2 remains unchanged. Studies have shown that adiponectin and its receptor are expressed in osteoblasts (mainly human osteoblasts of the femur and tibia). Studies have confirmed that AdipoR1 and AdipoR2 genes are expressed in both adipocytes and mesenchymal cells, and AdipoR1 expression levels in human subcutaneous and peritoneal omentum are about 10 times higher than AdipoR2. The study found that AdipoR is also expressed in human placenta, but mainly AdipoR1. Studies have found that pig AdipoR1 is highly expressed in the heart and skeletal muscle, while AdipoR2 is highly expressed in the subcutaneous adipose tissue. Other studies have found that the expression of AdipoR1 and AdipoR2 interacts positively, and the expression of both is positively correlated in human skeletal muscle. This may be because the regulatory site of gene expression control is regulated by the same transcription factor.
Figure 1. AdipoR2 activation pathway. (Okada-Iwabu M, et al. 2015)
AdipoR2-mediated Signal Transduction Pathway
Adiponectin receptors are key proteins that mediate the biological effects of adiponectin. Scatchard plot analysis showed that the active fragment of adiponectin, globular adiponectin (gAd), had a higher affinity with C2C12 myopocytic AdipoR1 (Kd=1.14nmol/L) and moderate affinity with AdipoR2 (Kd=14.4nmol/L). The full length adiponectin has a lower affinity with AdipoR1 (Kd = 2415nmol/L) and a central affinity with AdipoR2 (Kd=49.1nmol/L). This suggests that AdipoR1 is a high-affinity receptor for globular adiponectin and a low-affinity receptor for full-length adiponectin, while AdipoR2 is a medium-affinity receptor for full-length adiponectin and globular adiponectin. AdipoR1-/- mice exhibited obesity and impaired glucose tolerance. Mice with down-regulated AdipoR2 expression are resistant to insulin resistance induced by a high-fat diet. In the long-term high-fat diet, AdipoR2 does not function, limiting islet β cell proliferation and eventually develops type 2 diabetes.
T-cadherin is a receptor for adiponectin hexamers and macromolecular complexes, but due to the lack of intracellular domains, further studies are needed on the biological functions of adiponectin. AdipoR1/2 double knockout mice have significantly impaired glucose tolerance and hyperinsulinemia marked insulin resistance, and are prone to inflammation and oxidative stress. Because of the absence of an effective adiponectin receptor, adiponectin cannot bind to hepatocytes, suggesting that the biological function of adiponectin is mainly mediated by AdipoR1/2 and T-cadherin is weak.
AdipoR2 and T-cadherin with Breast Cancer
T-cadherin is a glycosylphosphatidylinositol-anchored protein that is considered to be an atypical adiponectin "receptor". At the genetic level, adiponectin, AdipoR2 and T-cadherin are most closely linked. Studies have shown that after adiponectin treatment, intracellular signaling pathways are first and mainly achieved by AdipoR2 and T-cadherin. Among them, T-cadherin assists AdipoR2 in transmitting adiponectin signaling. T-cadherin, in addition to affecting the progression of breast cancer through the associated pathways involved in adiponectin, is also involved in cell adhesion, which promotes invasion and metastasis of tumor cells. The study found that hypermethylation of T-cadherin in breast cancer patients suggests that this change promotes the development of breast cancer.
Studies have shown that adipoin can inhibit cell growth via AdipoR1 and prevent the transformation of ductal carcinoma in situ (DCIS) into invasive breast cancer. The higher the AdipoR2 expression, the higher the risk of lymphatic and vascular metastasis in the patient. AdipoR2 achieves this by increasing cyclooxygenase 2 (COX-2) and activating the peroxisome proliferator activated receptor-γ (PPAR-γ) signaling pathway. The result of both is to attenuate the activation of T cells by dendritic cells, leading to immune escape of tumor cells.
AdipoR2 and Hepatitis
Studies have shown that in hepatocytes and muscle cells, insulin can reduce AdipoR2 expression via a phosphatidylinositol 3-kinase/cross-head (PI3K/FOXO)-dependent pathway. Therefore, when insulin resistance occurs, excessive insulin can cause a decrease in AdipoR2, which leads to a decrease in its mediated adiponectin action. The study found that with the development of nonalcoholic steatohepatitis (NASH), the expression of AdipoR2 in the liver is also gradually decreasing as with adiponectin. In the further development of liver fibrosis, the expression of AdipoR2 is also gradually decreasing, which may be related to the progressive increase in systemic and/or local insulin resistance during the onset of NASH.
Studies have shown that adiponectin is mainly located in the endothelial cells of the human portal vein and sinus, while AdipoR2 is mainly located in the cytoplasm of hepatocytes. The location of adiponectin and AdipoR2 is different, suggesting that a paracrine pathway may be present to function. When NASH occurs, this pathway may be destroyed, blocking the role of adiponectin and leading to the development of NASH. The location of the distribution may also be inferred that AdipoR2 may also have direct liver protection when mediating the action of adiponectin.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.